抗体靶向治疗药物__培训课件.pptVIP

FDA 批准用于治疗肿瘤的抗体药物 Rituxan (1997): 非霍奇金B 细胞淋巴瘤 Herceptin (1998): 乳腺癌 Mylotarg (2000): 复发的急性髓细胞性白血病 Campath-1H (2001): 难治的慢性淋巴细胞白血病 Zevalin (2002): 难治的非霍奇金B 细胞淋巴瘤 Bexxar (2003): 难治的非霍奇金B 细胞淋巴瘤 Erbitux (2004): 结肠直肠癌 Avastin (2004): 结肠直肠癌 Vectibix (2006): 结肠直肠癌 单克隆抗体肿瘤靶向治疗 bind to antigens present preferentially or exclusively on tumor cells. Zevalin Bexxar Mylotarg 单克隆抗体作为肿瘤治疗的体内应用策略 Antibody Alone Complement mediated cytotoxicity (CMC) Antibody dependent cell-mediated cytotoxicity (ADCC) Regulatory (ligand/receptor) interactions Anti-idiotype vaccine Imm